医学
麻醉
不利影响
癌症疼痛
镇静剂
癌症
药理学
内科学
出处
期刊:PubMed
日期:2023-03-21
卷期号:103 (11): 793-802
标识
DOI:10.3760/cma.j.cn112137-20221105-02319
摘要
Patient-controlled intravenous analgesia (PCIA) is a common form of individualized treatment for cancer pain, and it has the characteristics of rapid onset, stable blood concentration and on-demand administration, which is suitable for patients who fail to take oral medicine or have poor pain control with oral medications. The preferred drugs for PCIA are strong opioids, which can be combined with sedative drugs according to the patient's condition. Dose titration is required prior to administration of PCIA, dynamic pain assessment should be performed during the use of PCIA, the dose should be adjusted at any time, and the adverse reactions should be closely monitored and treated in time. When pain control is stable, it can be transferred to home treatment. Therefore, PCIA has broad application prospects in patients with cancer pain due to its advantages of simple operation, relatively easy nursing care and controllable risk.患者静脉自控镇痛(PCIA)是癌痛患者个体化治疗的一种常用形式,PCIA具有起效迅速、血药浓度稳定、按需给药的特点,适用于不能口服或口服药物控制不佳的癌痛患者。PCIA首选用药为强阿片类药物,根据患者实际情况可适当联合镇静药物。在使用PCIA之前需要进行剂量滴定,使用过程中应进行疼痛动态评估,随时调整剂量,并严密监测患者的不良反应,及时对症处理,疼痛控制稳定后可转为居家治疗。PCIA因具有操作简单、护理相对容易、风险可控等优势,在癌痛患者的疼痛管理中具有广阔的应用前景。.
科研通智能强力驱动
Strongly Powered by AbleSci AI